news

CUPERTINO, Calif., Aug. 1 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Adams, Harkness & Hill Annual Summer Seminar. The conference is being held at the Boston Marriott Long Wharf Hotel. James E. Brown, DVM, President and Chief Executive Officer, will be presenting at the conference on Wednesday, August […]

CUPERTINO, Calif., July 22 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2005. DURECT’s net loss for the three months ended June 30, 2005 was $3.6 million or 7 cents per share, compared to a net loss of $7.4 million or 14 cents per share for

CUPERTINO, Calif., July 22 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that the Company has entered into a privately negotiated agreement with a holder of its 6.25% Convertible Subordinated Notes, due June 2008, to exchange up to $5 million in principal amount of convertible notes for 317.4603 shares of common stock per $1,000 principal

CUPERTINO, Calif., July 12 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the C. E. Unterberg, Towbin Emerging Growth Conference. The conference is being held at The Mandarin Oriental Hotel in New York, NY. Dr. James E. Brown, President and Chief Executive Officer, will be presenting at the conference on

CUPERTINO, Calif., July 11, 2005 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today the start of dosing in the third and final cohort of the Phase II dose escalation study in hernia patients in Australia for DURECT’s post-operative pain relief depot, SABER(TM)-Bupivacaine. The Company anticipates that approximately 60 patients will be enrolled in

CUPERTINO, Calif., July 8, 2005 /PRNewswire-FirstCall via COMTEX/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) second quarter 2005 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Friday, July 22, 2005 at 8:00 a.m. EDT. What: DURECT Corporation’s Second Quarter 2005

CUPERTINO, Calif., June 20 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today positive preliminary results from the second cohort of an on-going Phase II clinical study in hernia patients for DURECT’s post-operative pain relief depot product candidate, SABER(TM)-Bupivacaine. SABER-Bupivacaine is based on DURECT’s patented SABER delivery technology and is intended to be administered around the

CUPERTINO, Calif., May 24 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Friedman Billings Ramsey 9th Annual Growth Investor Conference. The conference is taking place June 1-2nd at The Millennium Broadway Hotel in New York City, New York. James E. Brown, DVM, President and Chief Executive Officer will be

CUPERTINO, Calif., May 3 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2005. DURECT’s net loss for the three months ended March 31, 2005 was $5.4 million or 10 cents per share, compared to a net loss of $6.0 million or 12 cents per share for

CUPERTINO, Calif., April 19 /PRNewswire-FirstCall/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) first quarter 2005 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Tuesday, May 3, 2005 at 4:30 p.m. EDT. What: DURECT Corporation’s First Quarter 2005 Earnings Conference Call